文献速递糖尿病

真实世界中的2型糖尿病:血糖控制之难

Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control.
PubMed 文献 · Diabetes Care · 2017-08-11

美国食品药品监督管理局(FDA)自2005年批准40余种2型糖尿病新药,但美国国家健康与营养调查显示糖化血红蛋白(HbA1c)<7.0%(<53 mmol/mol)达标率仅约50%,2003-2006与2011-2014年间几乎无变化。医疗效果数据与信息集报告商业保险(HMO)与医疗补助人群达标率仅约40%与30%,十年几乎无改善。近期回顾性队列研究显示真实世界HbA1c降幅远低于随机临床试验(RCT),用药依从性差是主要驱动因素。

要点

  • 美国2型糖尿病HbA1c<7.0%(<53 mmol/mol)达标率约50%,商业保险(HMO)与医疗补助人群仅约40%与30%。
  • 真实世界HbA1c降幅远低于随机临床试验(RCT),用药依从性差是主要驱动因素。
  • 用药依从性差在临床实践中常未被识别,亟需创新方法支持繁忙的医疗专业人员。

核心结论

  • FDA批准的2型糖尿病治疗选择日益增多,但真实世界血糖控制达标率未见改善,用药依从性差是关键驱动因素且常未被识别。

研究设计与样本

  • 本文为视角(Perspective)文章,综合美国国家健康与营养调查、医疗效果数据与信息集及一项基于美国大型理赔数据库的回顾性队列研究等数据。

主要发现

  • 美国国家健康与营养调查显示HbA1c<7.0%(<53 mmol/mol)达标率约50%,2003-2006与2011-2014年间下降可忽略不计。
  • 医疗效果数据与信息集报告商业保险(HMO)与医疗补助人群HbA1c<7.0%(<53 mmol/mol)达标率分别约40%与30%,过去十年几乎无变化。
  • 基于美国大型理赔数据库的回顾性队列研究发现,真实世界HbA1c降幅远低于随机临床试验(RCT)报告,用药依从性差是主要驱动因素。

临床怎么用

  • 作者认为,用药依从性差常因未被识别而在临床实践中尚未得到有效解决,亟需创新方法支持繁忙的医疗专业人员。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite U.S. Food and Drug Administration (FDA) approval of over 40 new treatment options for type 2 diabetes since 2005, the latest data from the National Health and Nutrition Examination Survey show that the proportion of patients achieving glycated hemoglobin (HbA1c) <7.0% (<53 mmol/mol) remains around 50%, with a negligible decline between the periods 2003-2006 and 2011-2014. The Healthcare Effectiveness Data and Information Set reports even more alarming rates, with only about 40% and 30% of patients achieving HbA1c <7.0% (<53 mmol/mol) in the commercially insured (HMO) and Medicaid populations, respectively, again with virtually no change over the past decade. A recent retrospective cohort study using a large U.S. claims database explored why clinical outcomes are not keeping pace with the availability of new treatment options. The study found that HbA1c reductions fell far short of those reported in randomized clinical trials (RCTs), with poor medication adherence emerging as the key driver behind the disconnect. In this Perspective, we examine the implications of these findings in conjunction with other data to highlight the discrepancy between RCT findings and the real world, all pointing toward the underrealized promise of FDA-approved therapies and the critical importance of medication adherence. While poor medication adherence is not a new issue, it has yet to be effectively addressed in clinical practice-often, we suspect, because it goes unrecognized. To support the busy health care professional, innovative approaches are sorely needed.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Edelman SV, Polonsky WH. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care. 2017. PMID: 28801473. doi:10.2337/dc16-1974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。